Search Results for "hansten"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for hansten. Results 21 to 30 of 433 total matches.

ThermaClear for Acne

   
The Medical Letter on Drugs and Therapeutics • Jun 18, 2007  (Issue 1263)
, Pharm.D. CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten, Pharm.D., University of Washington ...
The FDA has approved ThermaClear (Therative), a battery-powered, handheld device, to treat individual acne lesions with heat. ThermaClear is indicated only for use on mild to moderate inflammatory acne, not severe nodular or severe cystic acne, and it is not meant to be used on blackheads and whiteheads. Two similar devices are already on the market: Zeno, another handheld device that delivers heat to acne lesions, and the Radiancy Clear Touch Lite Acne Clearance System, a larger heat-delivery device.
Med Lett Drugs Ther. 2007 Jun 18;49(1263):51-2 |  Show IntroductionHide Introduction

Reducing Intake of Trans Fatty Acids

   
The Medical Letter on Drugs and Therapeutics • Aug 13, 2007  (Issue 1267)
. Hansten, Pharm.D., University of Washington ADVISORY BOARD: Jules Hirsch, M.D., Rockefeller University ...
...
Med Lett Drugs Ther. 2007 Aug 13;49(1267):65-6 |  Show IntroductionHide Introduction

Tinidazole (Tindamax) - A New Option for Treatment of Bacterial Vaginosis

   
The Medical Letter on Drugs and Therapeutics • Sep 10, 2007  (Issue 1269)
EDITOR, DRUG INTERACTIONS: Philip D. Hansten, Pharm.D., University of Washington ADVISORY BOARD ...
Tinidazole (Tindamax - Mission Pharmacal), an oral antiprotozoal drug available in the US since 2004 for treatment of trichomoniasis, giardiasis, amebiasis and amebic liver abscess, was recently approved by the FDA for treatment of bacterial vaginosis.
Med Lett Drugs Ther. 2007 Sep 10;49(1269):73-4 |  Show IntroductionHide Introduction

Eculizumab (Soliris) for Paroxysmal Nocturnal Hemoglobinuria

   
The Medical Letter on Drugs and Therapeutics • Sep 24, 2007  (Issue 1270)
: Jean-Marie Pflomm, Pharm.D. CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten, Pharm.D ...
Eculizumab (Soliris - Alexion) has been approved by the FDA for reduction of hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare form of hemolytic anemia. A recombinant humanized monoclonal antibody, eculizumab is the first drug to be marketed for this indication.
Med Lett Drugs Ther. 2007 Sep 24;49(1270):79-80 |  Show IntroductionHide Introduction

BRCA Screening

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 2007  (Issue 1274)
: Jean-Marie Pflomm, Pharm.D. CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten, Pharm.D ...
Direct-to-consumer advertisements are urging women to be tested for mutations in BRCA1 and BRCA2 genes, which are the most common known causes of an inherited predisposition to breast and ovarian cancer. Clinically important BRCA mutations have been found in about 2% of Ashkenazi Jewish women, and are estimated to occur in about 1 in 300 to 500 women in the general non-Jewish US population. The prevalence appears to be lower in non-whites.
Med Lett Drugs Ther. 2007 Nov 19;49(1274):93-4 |  Show IntroductionHide Introduction

Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures

   
The Medical Letter on Drugs and Therapeutics • Dec 03, 2007  (Issue 1275)
: Jean-Marie Pflomm, Pharm.D. CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten, Pharm.D ...
The American Heart Association has issued its revised guidelines for prevention of infective endocarditis. Antimicrobial prophylaxis for dental procedures is now recommended only for patients at the highest risk of severe consequences from endocarditis who are undergoing the highest-risk procedures. Endocarditis prophylaxis is no longer recommended for gastrointestinal (GI) and genitourinary (GU) procedures. When these changes are implemented, the number of patients receiving antimicrobial prophylaxis to prevent endocarditis should decline sharply.
Med Lett Drugs Ther. 2007 Dec 3;49(1275):99-100 |  Show IntroductionHide Introduction

Aspirin For Primary Prevention of Cardiovascular Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 21, 2000  (Issue 1072)
. CONTRIBUTING EDITORS: Philip D. Hansten, Pharm. D., University of Washington; Neal H. Steigbigel, M.D., Albert ...
Some readers have asked whether the widespread practice of taking aspirin to prevent first heart attacks is justifiable and, if so, what the dose should be. Only one large well-designed study has tested the use of aspirin for this purpose.
Med Lett Drugs Ther. 2000 Feb 21;42(1072):18 |  Show IntroductionHide Introduction

In Brief: Airborne

   
The Medical Letter on Drugs and Therapeutics • Jan 03, 2005  (Issue 1199)
., Rockefeller University ADVISORY BOARD: Philip D. Hansten, Pharm. D., University of Washington Jules Hirsch ...
Patients may be asking about Airborne, a dietary supplement that is being heavily promoted for prevention and treatment of colds. It contains 7 herbal extracts, 3 vitamins, 2 amino acids, selenium, zinc and many other ingredients. Airborne Jr is available for children. There are some concerns. First, there is no conclusive evidence that this product or any of its ingredients prevents colds or shortens their duration. Second, the adult tablet contains 1 g of vitamin C, and the directions for use advise taking 1 tablet at the first sign of a cold and repeating the dose every 3 hours as...
Med Lett Drugs Ther. 2005 Jan 3;47(1199):4 |  Show IntroductionHide Introduction

In Brief: Rhabdomyolysis with Ezetimibe

   
The Medical Letter on Drugs and Therapeutics • Feb 28, 2005  (Issue 1203)
., Rockefeller University ADVISORY BOARD: Philip D. Hansten, Pharm. D., University of Washington Jules Hirsch ...
Health Canada, the Canadian equivalent of the FDA, recently issued a public advisory about postmarketing reports of myalgia, rhabdomyolysis, hepatitis, pancreatitis and thrombocytopenia associated with use of ezetimibe (Zetia in the US; Ezetrol in Canada). Ezetimibe is often added to a statin to increase LDL cholesterol lowering (Drugs for Lipids, Treat Guidel Med Lett 2005; 3:15). The advisory did not specify whether these patients were also taking a statin, but according to the Canadian manufacturer Merck Frosst/Schering (Merck/Schering-Plough in the US), some of the patients who developed...
Med Lett Drugs Ther. 2005 Feb 28;47(1203):17 |  Show IntroductionHide Introduction

In Brief: Adderall

   
The Medical Letter on Drugs and Therapeutics • Mar 28, 2005  (Issue 1205)
OF DRUG INFORMATION: Jean-Marie Pflomm, Pharm.D. ADVISORY BOARD: Philip D. Hansten, Pharm. D ...
On February 9, 2005, Health Canada suspended the marketing of Adderall XR (Shire), a mixture of amphetamine salts used to treat attention-deficit hyperactivity disorder (ADHD) (Med Lett Drugs Ther 1994; 36:109). The immediate-release form of Adderall was never marketed in Canada. The withdrawal was based on 20 reports internationally of sudden death in patients taking the drug. These deaths, 14 of them in children, were not linked to overdose or abuse. The FDA decided that the number of sudden deaths was no greater than expected among the large number of people taking the drug, but because 5...
Med Lett Drugs Ther. 2005 Mar 28;47(1205):28 |  Show IntroductionHide Introduction